The Latest Breaking News from Pfizer

Some people have had trouble getting Paxlovid pills quickly, despite the administration's effort to ease access after a COVID test confirms infection.

Paxlovid, Pfizer’s antiviral treatment for COVID-19, is turning out to be one of the most successful new drugs in pharma history. Prescriptions have increased tenfold since February, and the five-day pill pack accounts for nearly 90% of the COVID-19 oral-antiviral market.

Someone with a lot of money to spend has taken a bullish stance on Pfizer (NYSE:PFE). And retail traders should know. We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga.

The head of the World Health Organization has called on Pfizer to make its COVID-19 treatment more widely available in poorer countries

Unvaccinated pregnant women who catch Covid-19 are more likely to fall seriously ill

Here's a roundup of top developments in the biotech space over the last 24 hours:

Pfizer will acquire migraine drugmaker Biohaven Pharmaceuticals for nearly $12 billion in a deal that sent BHVN stock rocketing.

Pfizer Inc (NYSE:PFE) will acquire Biohaven Pharmaceutical Holding Company Ltd (NYSE:BHVN) for $148.50 per share, equivalent to $11.6 billion.  Pfizer will also make payments at closing to settle Biohaven's third-party debt and for the redemption of all outstanding shares of Biohaven's redeemable preferred stock.  The deal includes the acquisition of rimegepant (NURTEC ODT), a dual-acting…

Pfizer is spending $11.6 billion to buy the remaining portion of migraine treatment maker Biohaven Pharmaceuticals it does not already own

It is "over and above" the level of protection that people who have had their third jab receive, according to the latest research.

Chance of stillbirth reduced by 15%, researchers find, after examining studies and trials that enrolled 117,552 women